Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Trial Details

NCT ID

NCT07291037

Phase

PHASE3

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Datopotamab deruxtecan (Dato-DXd)
• Docetaxel

Locations (sample)

• Chandler, Arizona, United States|33.30616,-111.84125
• Gilbert, Arizona, United States|33.35283,-111.78903
• Goodyear, Arizona, United States|33.43532,-112.35821
• Duarte, California, United States|34.13945,-117.97729
• Irvine, California, United States|33.66946,-117.82311

Key Eligibility Criteria

• Pathologically documented Stage IIIB, IIIC, or Stage IV non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA…
• Participants must have documented negative test results for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS prot…
• Has no known tumour genomic alterations in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfectio…
• Prospectively assessed trophoblast cell surface protein 2 (TROP2) normalised membrane ratio (NMR) positive.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.